Zydus Cadila receives final approval from USFDA for Aspirin and extended release Dipyridamole capsules
Mumbai: Pharma major, Zydus Cadila said that company received final approval from the US Food and Drug Administration (USFDA) to market Aspirin and extended release Dipyridamole capsules in the strengths of 25mg/ 200mg.
The Drug is an antiplatelet agent which works in prevention of excessive blood clotting and reduce the risk of strokes in patients who have has or risk to stroke company said in a filing with BSE.
Drugs will be manufactured at its formulations manufacturing facility at Moraiya in Ahmedabad, filing added
The company has more than 140 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd